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The Universal Data Collection (UDC) System 
Lessons Learned and Future Directions
Hemophilia and other bleeding disorders can cause lifelong problems 
and complications. The Centers for Disease Control and Prevention (CDC) 
established the Universal Data Collection (UDC) system to gather information 
about complications that occur among patients receiving care in hemophilia 
treatment centers (HTCs) throughout the United States. Researchers are using 
this information to learn more about why some people with bleeding disorders 
develop complications while others do not.
What have we learned from UDC?
The UDC system was designed to monitor trends and changes over time, so 
some of the analyses are just beginning. However, many articles have been 
published describing the findings to date. Following are a few of the areas in 
which some of these findings are detailed:
Joint Health
Joint infections are a rare 
complication of hemophilia and occur 
mostly in target joints or in joints that 
have undergone joint surgery.
Males with hemophilia who are 
overweight are more likely to have 
less mobility in their joints than 
those who are not overweight.
Inhibitors
The rate of new inhibitors among 
previously treated patients with 
hemophilia is very low, but more 
study is needed to determine why 
they occur.
People with inhibitors are at 
higher risk for joint disease and 
other complications from bleeding, 
resulting in reduced quality of life.
Treatment Practice
Treatment practices (such as 
prophylaxis, which is regularly 
scheduled treatment using clotting 
factor to prevent bleeding) differ 
among HTCs. Further study is 
needed to understand why these 
differences exist.
Prophylaxis appears to decrease 
bleeding inside the head (which is 
known as intracranial hemorrhage) 
among patients with severe 
hemophilia who do not have an 
inhibitor or human immunodeficiency 
virus (HIV). 
Babies
The most common sites of bleeding 
among babies are the circumcision site 
and the head (either inside or outside 
the skull). Bleeding inside the head 
(intracranial hemorrhage) is a serious 
complication and results in serious 
brain injury among 20% of patients.
More than 70% of the 580 babies 
with hemophilia enrolled in UDC 
from 2003 to 2007 reported having 
a bleeding episode before 2 years of 
age, and one in five of these bleeds 
involved the head.
In the United States, most people 
with hemophilia are diagnosed at a 
very young age. Half of those people 
with mild hemophilia are diagnosed 
by 3 years of age, half of those with 
moderate hemophilia by 8 months 
of age, and half of those with severe 
hemophilia by 1 month of age. 
Academic Achievement
Men with hemophilia A graduate 
from high school at a similar 
or higher rate than the national 
population of men.
The UDC system monitors major 
complications of bleeding 
disorders, such as:
•	 Developing or worsening 
joint disease, or both
•	 Developing inhibitors ( a 




•	 Acquiring diseases such as 
hepatitis and acquired 
immune deficiency 
syndrome (AIDS) through 
blood products
Overweight and Obesity
Youth with hemophilia are just 
as likely to be overweight as youth 
among the general population; 
however, the extra weight puts 
them at increased risk for long-term 
damage to their joints.
Males with hemophilia who are 
overweight are more likely to have 
less joint mobility than those who are 
not overweight.
Blood Safety
Since 1998, no new infections of 
hepatitis A, hepatitis B, hepatitis C, or 
HIV have been linked to using blood 
products to treat bleeding disorders.
Samples of stored blood from 
UDC system participants from the 
early days of the West Nile virus 
epidemic (2002–2003; before the virus 
spread across the country) showed 
no evidence of spread of the virus 
through clotting factor products.
In 2004, a study of stored blood 
showed that very young children 
who used plasma-derived clotting 
factor products were more likely to 
have been exposed to parvovirus 
B19 infection. This led to increased 
testing as part of the manufacture of 
these products.
Changes in Causes of 
Mortality
Among deaths of people with 
bleeding disorders reported to CDC 
during the period 1997–2007, the 
most common causes were related to 
HIV (19%) and liver disease (22%). 
Hemophilia-related (bleeding) causes 
were less common (12%).
What studies currently are being 
conducted using UDC system data?
HTC investigators are busy looking at the UDC system 
data to find out more about:
•	Inhibitors and ways to find and measure them.
•	Links (if any) between the type of genes a person  
has and if the person will develop an inhibitor.
•	Joint disease among people with severe von 
Willebrand disease. 
•	Hereditary bleeding disorders among women. 
•	Causes and consequences of bleeding in or around 
the brain. 
•	Use of routine preventive treatment. 
•	Use of devices that allow health care providers access 
to a patient’s vein to provide treatment or draw 
blood. 
•	Joint disease and how it progresses among people 
who already have damaged joints.
•	Parvovirus B19 and whether the testing the 
manufacturing companies are doing has decreased 
the risk of this infection from clotting factor.
•	The extent of vaccination among the community 
with bleeding disorders and the effectiveness of 
prevention messages.
What future studies are planned?
Researchers plan to study:
•	Reasons why some children with hemophilia have 
more loss of joint mobility than others, even though 
they do not bleed more often.
•	Bleeding symptoms and other signs of severe von 
Willebrand disease.
•	Complications among children with hemophilia who 
are younger than 2 years of age.
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